HDFC Bank Limited Common Stock vs uniQure N.V. Ordinary Shares — how do they compare? HDFC Bank Limited Common Stock trades at $23.01 (market cap $115.00B), while uniQure N.V. Ordinary Shares trades at $21.51 (market cap $1.45B). The key difference: HDFC Bank Limited Common Stock is far larger — about 79.3× uniQure N.V. Ordinary Shares's market cap, and HDFC Bank Limited Common Stock pays a 1.81% dividend while uniQure N.V. Ordinary Shares pays none. Which is the better fit depends on your goals — on Pluang, investors hold HDFC Bank Limited Common Stock for 6 Days and uniQure N.V. Ordinary Shares for 0 Days on average.
| HDB | QURE | |
|---|---|---|
Market Cap | $115.00B | $1.45B |
Volume | 5,621,803 | 3,323,243 |
Sector | Financials | Health |
52-Week High | $37.18 | $70.59 |
52-Week Low | $21.84 | $9.03 |
Typical Hold Time | 6 Days | 0 Days |
Enterprise Value | $14.49T | $707.46M |
Dividend Yield | 1.81% | — |
Signals from Pluang's Aura AI — not financial advice
HDFC Bank (HDB) trades at $22.76, up 0.8% with neutral technical indicators. The bank maintains strong profitability with 28.24% net income margin and consistent earnings beats. However, significant legal headwinds emerge as multiple class action lawsuits approach deadlines in October 2026, creating investor uncertainty despite solid fundamentals.
While HDB demonstrates financial strength with improving debt-to-asset ratios and positive cash flow projections for 2026, the pending securities litigation represents a material risk. Analyst consensus leans cautious with 67% hold ratings, suggesting investors await legal clarity before more bullish positioning despite attractive valuation metrics.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
HDFC Bank provides retail, wholesale, and treasury banking services in India. Its offerings include deposits, lending, payments, trade finance, and financial services for individuals and businesses.
Read more on HDB →uniQure N.V. is a biotechnology company that develops gene therapies for rare and severe genetic diseases, marketing HEMGENIX for hemophilia B and advancing its AAV-based miQURE platform in programs such as AMT-130 for Huntington's disease.
Read more on QURE →